Kuntz, MD, was a fellow about 45 years ago, there were few more devastating diagnoses than Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sales of Elevidys are quickly gaining ground on Sarepta's exon-skipping trio, which need to be dosed chronically. In the ...

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

The global Duchenne muscular dystrophy (DMD) therapeutics market is set to grow by $4.4 billion from 2024 to 2028, with a ...

According to the Mayo Clinic, muscular dystrophy is a group of diseases that cause loss of muscle mass and progressive ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

Wave Life Sciences Pte. Ltd ( (WVE) ) has released its Q3 earnings. Here is a breakdown of the information Wave Life Sciences Pte. Ltd ...

Pratteln, Switzerland, November 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive supply agreement with Ali Al Suwaidi Trading Est. (ASTE) for the treatment of ...

The former No. 1 draft pick got his third win as an NFL quarterback on Sunday. The AFC East is just about wrapped up, and ...

We have studied such a kindred, in which 9 males have a clinically distinct X-linked muscular dystrophy that significantly differs from the Duchenne form. Moreover, using multiple diagnostic ...